MEXICO CAN ELIMINATE HEPATITIS
NATIONAL HEPATITIS ELIMINATION PROFILE

Hepatitis B virus (HBV)  
NO  HBV elimination goal

Hepatitis C virus (HCV)  
2030  HCV elimination goal

THE HEALTH BURDEN OF VIRAL HEPATITIS

0.1-0.2%  Number of persons living with HBsAg \(^3\)\(^,\)\(^18\)  
Based on modeled data

0.4-2.2%  Number of persons living with HCV infection \(^4\)  
REGION AVERAGE IN THE AMERICAS:  
HBV: 0.3%  
HCV: 0.7%  
Based on modeled data and studies among blood donors

803  New HBV cases, 2019 \(^5\)  
New cases reported, not necessarily incidence \(^2\)

2,100  New HCV cases, 2019 \(^5\)  
New cases reported, not necessarily incidence \(^2\)
2,125 HBV deaths, 2019 \(^4\) \(1.7\)
Deaths per 100,000 \(^4\)

13,737 HCV deaths, 2019 \(^4\)
Deaths per 100,000 \(^4\)

PROGRESS TOWARDS 2020 WHO ELIMINATION GOALS

PREVENTION OF NEW INFECTIONS AND MORTALITY

<table>
<thead>
<tr>
<th>Disease</th>
<th>Percentage change in new infections, 2015-2019</th>
<th>WHO 2020 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV</td>
<td>+7%</td>
<td>-30% (^1)</td>
</tr>
<tr>
<td>HBV</td>
<td>+30%</td>
<td>-10% (^4)</td>
</tr>
<tr>
<td>HCV</td>
<td>+13%</td>
<td>-30% (^3)</td>
</tr>
<tr>
<td>HCV</td>
<td>+19%</td>
<td>-10% (^4)</td>
</tr>
</tbody>
</table>

Prevalence of HBsAg in children < 5 years (%), 2019 \(^4\)
0.02%  
SDG 2020 Target 1\% \(^4\)

ACCESS TO RECOMMENDED VACCINATION, TESTING AND TREATMENT

81% Hepatitis B vaccination coverage for newborns, 2020 \(^10\)

WHO 2020 Target 50\% \(^11\)
**MEXICO • HEPATITIS ELIMINATION PROFILE**

**COALITION FOR GLOBAL HEPATITIS ELIMINATION**

**HepB 3 dose vaccine coverage for infants, 2020**

- **WHO 2020 Target 90%**

**Proportion of diagnosed HBV persons receiving appropriate treatment**

- **NO DATA**

**For persons who inject drugs (PWID), number of sterile needles per year 2015**

- **WHO 2020 Target 200**

**Proportion of persons with HBV diagnosed**

- **NO DATA**

**Proportion of persons living with HCV diagnosed**

- **NO DATA**

**Proportion of persons who have cleared HCV infection**

- **NO DATA**
## POLICY ENVIRONMENT FOR THE ELIMINATION OF HEPATITIS

### ACHIEVEMENTS

#### STRATEGIC INFORMATION

- **Routine official reports to monitor HBV and HCV** \(^{11}\)
- **Estimates of HBV and/or HCV economic burden** \(^{13,14}\)
- **Monitoring of HBV and HCV diagnosis and treatment** \(^{15,16}\)

### INNOVATIONS

- **Development of a sectoral information system, “AAMATES”, which will include information from public health institutions on the results of HCV treatment and tests.**

### ROADBLOCKS

- **Mortality**
- **Incidence**
- **Prevalence**

- **SDG**
- **Only for HCV**
- **Survey-based estimates are older than 5 years**

### PREVENTION OF MOTHER TO CHILDREN TRANSMISSION

- **Policy for hepatitis B vaccination of newborns** \(^{1a}\)
- **Recommendations for:**
  - **HBV testing of pregnant women** \(^{1}\)
  - **HCV testing of pregnant women** \(^{17}\)

### ACCESS AND REGISTRATION OF MEDICINES AND TESTS

- **HCV:** **Registration of originator medicines** \(^{31}\)
- **HCV:** **Eligible for generic medicines**
- **HCV:** **Registration of generic medicines**

---

Country not included in the DCV license (or for SOF and G / P). However, provision by MPP licensees is permitted if no patent is infringed and the licensee does not rely on BMS technology.
Licensed point-of-care PCR testing to detect HBV and HCV

**TESTING TO DIAGNOSE HBV AND HCV INFECTION**

Testing recommendations for:

- **HBV**: Risk-based
  - Partially Adopted

- **HCV**: Risk-based
  - Adopted

- **HBV**: General population
  - Not Adopted

- **HCV**: General population
  - Adopted

No patient co-pays for HBsAg and anti-HCV testing

**ACHIEVEMENTS**

More than 98,000 people living with HIV have been screened for hepatitis C, diagnosing more than 1,200 people living with both HIV and HCV and initiating treatment.

**ROADBLOCKS**

Need to improve diagnosis rates and reach vulnerable populations.

No hepatitis B testing strategy developed.

**ACCESS TO HBV AND HCV TREATMENT**

- **HBV**: Local treatment guidelines
  - No Data

  Simplified care: Simplified treatment and follow-up algorithm for primary care physicians
  - No Data

  Simplified care algorithm: No patient treatment co-pays
  - No Data
**HCV:**
- Local treatment guidelines
  - Developed
- Simplified care algorithm: Less than 2 clinic visits during treatment
  - Adopted
- Simplified care algorithm: Non-specialists can prescribe treatment
  - Adopted
- Simplified care algorithm: No patient treatment co-pays
  - Adopted
- No fibrosis restrictions
  - Adopted
- No sobriety restrictions
  - Adopted
- No genotyping
  - Adopted

**INNOVATIONS**
*Implementation of a telementoring program and networks, with evaluation of complex cases by a multidisciplinary team through information technologies, with the aim of bringing specialist doctors and other health professionals, experts on the subject, to remote places; enables the training of first-level personnel and creates effective care networks.*

**ACHIEVEMENTS**
- More than 90% of people with a diagnosis of HIV and hepatitis C coinfection have access to treatment.
- Diagnosis and treatment is now authorized in the public sector to the entire population at no out-of-pocket cost to any individual.
- 394 strategic units of care for the HCV program established.
- 394 strategic units of care for the HCV program established.

**ROADBLOCKS**
*Greater dissemination of hepatitis C treatment guidelines and action plan is needed.*
## Health Equity and Addressing Disparities

<table>
<thead>
<tr>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>National strategy addresses populations most affected (that is, people who inject drugs, indigenous people, MSM, coinfected, etc.)</td>
<td>Adopted</td>
</tr>
<tr>
<td>National anti-discrimination laws against persons living with hepatitis B and/or C</td>
<td>Partially Adopted</td>
</tr>
<tr>
<td>National policy for adult hepatitis B vaccination</td>
<td>Adopted</td>
</tr>
<tr>
<td>National policy for:</td>
<td></td>
</tr>
<tr>
<td>Harm reduction for persons who inject drugs (PWID)</td>
<td>Partially Adopted</td>
</tr>
<tr>
<td>Syringe exchange in federal prisons</td>
<td>Not Adopted</td>
</tr>
<tr>
<td>If yes, number of federal prisons implementing syringe exchange</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Number of needles/syringes per PWID per year</td>
<td>5.235</td>
</tr>
<tr>
<td>Number of opioid substitution therapy recipients per 100 PWID</td>
<td>No Data</td>
</tr>
<tr>
<td>Decriminalization of possession of syringes &amp; paraphernalia</td>
<td>Adopted</td>
</tr>
<tr>
<td>Decriminalization of drug use</td>
<td>Partially Adopted</td>
</tr>
</tbody>
</table>

- The hepatitis B vaccine is recommended for “high risk” groups and healthcare workers.

### Who Inject Drugs (PWID) 15

- Syringe exchange in federal prisons

### National Anti-Discrimination Laws Against Persons Living with Hepatitis B and/or C 1

- National policy for adult hepatitis B vaccination

### National Policy for Adult Hepatitis B Vaccination

- National policy for:
  - Harm reduction for persons who inject drugs (PWID)
  - Syringe exchange in federal prisons

### National Policy for:

- Number of needles/syringes per PWID per year
- Number of opioid substitution therapy recipients per 100 PWID
- Decriminalization of possession of syringes & paraphernalia
- Decriminalization of drug use

### WHO 2020 Target 200

- Number of needles/syringes per PWID per year
- No Data

### Development of Care Guide for Patients Living with Hepatitis C

- The incorporation of community leaders into the elimination program, with the aim of expanding the program by facilitating and expanding access.

### Creation of Detection Programs Focused on Populations with the Highest Prevalences of the Disease

- The incorporation of community leaders into the elimination program, with the aim of expanding the program by facilitating and expanding access.

### Involvement of Community Leaders into the Elimination Program

- The incorporation of community leaders into the elimination program, with the aim of expanding the program by facilitating and expanding access.

### Populations Deprived of Their Liberty

- People deprived of their liberty, blood donors.

###共创检测计划

- 病毒携带者和艾滋病毒携带者

###社会参与

- 社区领导的参与，以扩大和改善计划的实施。
Public budget line for HBV and HCV testing and treatment

**FINANCING**

Adopted

**NEXT STEPS TOWARD ELIMINATION**

- Develop a HBV action plan and set HBV elimination goals.
- Ensure efficient recording of information from data systems to inform planning and implementation.
- Add new technologies to track people with a cure and implement programs for hard-to-reach people (homeless, people who inject drugs, migrants).
- Identify strategies for screening by regions and priority groups.
- Encourage the publication of epidemiological and clinical evidence, already generated through the program.
- Evaluate the program one year after it is implemented with the participation of those affected.
- Optimize the process of diagnosis and access to treatment.
- Expand the EDUCADS program.
- Continue socializing the elimination program.
- Consolidate the elimination program by setting annual targets.
- Implement a program that allows the activation of people’s health, to reduce the risk of new infections.
- Ensure the transparency and fairness of the elimination program at all steps.
SOURCES


7. RDA, 2021

8. RDA, 2020


17. “GUÍA RÁPIDA PARA LA ATENCIÓN DE PERSONAS CON VIRUS DE LA HEPATITIS C (VHC) EN LOS ESTABLECIMIENTOS DE SALUD” Secretaría de Salud de México


WORKING TOGETHER, WE WILL ACHIEVE ELIMINATION.

This National Hepatitis Elimination Profile (N-HEP) was developed by the Coalition for Global Hepatitis Elimination. Funding for this N-HEP was provided by Gilead Sciences. The Coalition for Global Hepatitis Elimination retained final control over the content.

The Coalition thanks the National Observatory for the Elimination of Hepatitis C of Mexico for its review and comments on the data. The Coalition also thanks Dr. Kershenobich of the National Institute of Medical Sciences and Nutrition “Salvador Zubirán” (INCMNSZ) and Nicole Finkelstein of the AIDS Healthcare Foundation for their contributions. The Coalition also thanks the Pan American Health Organization for its technical review and guidance in developing the national hepatitis elimination profiles.